[go: up one dir, main page]

MA38206B1 - Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées - Google Patents

Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Info

Publication number
MA38206B1
MA38206B1 MA38206A MA38206A MA38206B1 MA 38206 B1 MA38206 B1 MA 38206B1 MA 38206 A MA38206 A MA 38206A MA 38206 A MA38206 A MA 38206A MA 38206 B1 MA38206 B1 MA 38206B1
Authority
MA
Morocco
Prior art keywords
hydrazones
tuberculosis
pyridyl
related diseases
treatment
Prior art date
Application number
MA38206A
Other languages
English (en)
Other versions
MA38206A1 (fr
Inventor
Ferreira Ana Lúcia Almeida
Ana Sofia Lopes
Filipe Augusto Eugénio Pardal
Carlos Caixado
Pedroso Pedro Filipe Eufrásio
Almeida Pecorelli Susana Marques De
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA38206A1 publication Critical patent/MA38206A1/fr
Publication of MA38206B1 publication Critical patent/MA38206B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des pyridyl-hydrazones de formule (i), ou des sels, esters, solvates, isomères et promédicaments pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques contenant ces composés, à utiliser pour le traitement prophylactique et/ou thérapeutique de la tuberculose et de maladies associées, par exemple, des maladies causées par des mycobactéries non tuberculeuses et/ou par
MA38206A 2012-11-20 2013-11-20 Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées MA38206B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106652A PT106652A (pt) 2012-11-20 2012-11-20 Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas
PCT/PT2013/000068 WO2014081324A1 (fr) 2012-11-20 2013-11-20 Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Publications (2)

Publication Number Publication Date
MA38206A1 MA38206A1 (fr) 2017-12-29
MA38206B1 true MA38206B1 (fr) 2019-03-29

Family

ID=49876952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38206A MA38206B1 (fr) 2012-11-20 2013-11-20 Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Country Status (15)

Country Link
US (1) US9593103B2 (fr)
EP (2) EP2922541B1 (fr)
BR (1) BR112015011606A2 (fr)
CY (2) CY1121861T1 (fr)
DK (1) DK2922541T3 (fr)
ES (2) ES2899437T3 (fr)
HR (2) HRP20211767T1 (fr)
HU (2) HUE045502T2 (fr)
LT (2) LT2922541T (fr)
MA (1) MA38206B1 (fr)
PL (2) PL2922541T3 (fr)
PT (3) PT106652A (fr)
RS (2) RS59224B1 (fr)
SI (2) SI3539543T1 (fr)
WO (1) WO2014081324A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115590857B (zh) * 2021-07-08 2024-11-05 中国医学科学院药物研究所 化合物t0349在制备抗结核分枝杆菌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3716131A1 (de) * 1987-05-14 1988-12-01 Forsch Borstel Inst Fuer Exper Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel
US8865901B2 (en) * 2009-10-02 2014-10-21 Fred Hutchinson Cancer Research Center Gain-of-function Bcl-2 inhibitors
EP2311457A1 (fr) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Compositions pharmaceutiques pour traiter les infections avec des mycobactéries résistantes aux médicaments

Also Published As

Publication number Publication date
BR112015011606A2 (pt) 2017-07-11
HUE056531T2 (hu) 2022-02-28
PL2922541T3 (pl) 2019-10-31
EP3539543A1 (fr) 2019-09-18
ES2741434T3 (es) 2020-02-11
US9593103B2 (en) 2017-03-14
MA38206A1 (fr) 2017-12-29
RS59224B1 (sr) 2019-10-31
EP3539543B1 (fr) 2021-09-01
PL3539543T3 (pl) 2022-01-10
CY1124836T1 (el) 2022-11-25
RS62579B1 (sr) 2021-12-31
EP2922541A1 (fr) 2015-09-30
US20150284374A1 (en) 2015-10-08
LT2922541T (lt) 2019-09-25
DK2922541T3 (da) 2019-08-12
PT2922541T (pt) 2019-08-26
WO2014081324A1 (fr) 2014-05-30
HRP20191402T1 (hr) 2019-11-15
LT3539543T (lt) 2021-12-27
EP2922541B1 (fr) 2019-05-22
HUE045502T2 (hu) 2019-12-30
CY1121861T1 (el) 2020-07-31
SI2922541T1 (sl) 2019-10-30
ES2899437T3 (es) 2022-03-11
PT3539543T (pt) 2021-11-22
SI3539543T1 (sl) 2022-01-31
PT106652A (pt) 2014-05-20
HRP20211767T1 (hr) 2022-02-18

Similar Documents

Publication Publication Date Title
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA44674A (fr) Inhibiteurs de bromodomaine
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
NZ708593A (en) Novel pyrazole derivative
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
GEAP202215599A (en) Boron containing pde4 inhibitors
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA34746B1 (fr) Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques
MA38206B1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA38207A2 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées